

Using Real-World Data to Predict Findings of an Ongoing Outcome Trial: Cardiovascular Safety of Linagliptin Versus

Diabetes Care

42, 2204-2210

DOI: [10.2337/dc19-0069](https://doi.org/10.2337/dc19-0069)

Citation Report

#	ARTICLE	IF	CITATIONS
2	A Verdict for Glimepiride: Effective and Not Guilty of Cardiovascular Harm. <i>Diabetes Care</i> , 2019, 42, 2161-2163.	4.3	13
3	When Randomized Clinical Trials and Real-World Evidence Say the Same: Tocilizumab and Its Cardiovascular Safety. <i>Arthritis and Rheumatology</i> , 2020, 72, 4-6.	2.9	7
4	A review of big data and medical research. <i>SAGE Open Medicine</i> , 2020, 8, 205031212093483.	0.7	45
5	Real-world evidence: the devil is in the detail. <i>Diabetologia</i> , 2020, 63, 1694-1705.	2.9	38
6	Effectiveness and Safety of Apixaban Compared With Rivaroxaban for Patients With Atrial Fibrillation in Routine Practice. <i>Annals of Internal Medicine</i> , 2020, 172, 463.	2.0	72
7	University of Pennsylvania 12th annual conference on statistical issues in clinical trials: Electronic health records in randomized clinical trials—challenges and opportunities (morning panel session). <i>Clinical Trials</i> , 2020, 17, 405-413.	0.7	0
8	Bias Implications of Outcome Misclassification in Observational Studies Evaluating Association Between Treatments and All-Cause or Cardiovascular Mortality Using Administrative Claims. <i>Journal of the American Heart Association</i> , 2020, 9, e016906.	1.6	12
9	Replication of randomized clinical trial results using real-world data: paving the way for effectiveness decisions. <i>Journal of Comparative Effectiveness Research</i> , 2020, 9, 1043-1050.	0.6	15
10	Practical use of electronic health records among patients with diabetes in scientific research. <i>Chinese Medical Journal</i> , 2020, 133, 1224-1230.	0.9	1
11	Serious infection risk in children with psoriasis on systemic treatment: A propensity score-matched population-based study. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 1337-1345.	0.6	9
12	Emulation Differences vs. Biases When Calibrating Real-World Evidence Findings Against Randomized Controlled Trials. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 735-737.	2.3	27
13	Transparency in real-world evidence (RWE) studies to build confidence for decision-making: Reporting RWE research in diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 45-59.	2.2	14
14	Effect of linagliptin, a dipeptidyl peptidase-4 inhibitor, compared with the sulfonylurea glimepiride on cardiovascular outcomes in Asians with type 2 diabetes: subgroup analysis of the randomized CAROLINA [®] trial. <i>Diabetology International</i> , 2021, 12, 87-100.	0.7	12
15	Dupilumab and the risk of conjunctivitis and serious infection in patients with atopic dermatitis: A propensity score-matched cohort study. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 300-311.	0.6	20
16	Contemporary use of real-world data for clinical trial conduct in the United States: a scoping review. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2021, 28, 144-154.	2.2	33
17	Emulating Randomized Clinical Trials With Nonrandomized Real-World Evidence Studies. <i>Circulation</i> , 2021, 143, 1002-1013.	1.6	174
18	Biases in Evaluating the Safety and Effectiveness of Drugs for the Treatment of COVID-19: Designing Real-World Evidence Studies. <i>American Journal of Epidemiology</i> , 2021, 190, 1452-1456.	1.6	24
19	Real-world evidence of bariatric surgery and cardiovascular benefits using electronic health records data: A lesson in bias. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1453-1462.	2.2	12

#	ARTICLE	IF	CITATIONS
21	Prescribing trends and clinical characteristics of patients starting antiobesity drugs in the <scp>United States</scp>. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1542-1551.	2.2	23
22	Conducting Real-world Evidence Studies on the Clinical Outcomes of Diabetes Treatments. <i>Endocrine Reviews</i> , 2021, 42, 658-690.	8.9	50
23	Expert Consensus on Telemedicine Management of Diabetes (2020 Edition). <i>International Journal of Endocrinology</i> , 2021, 2021, 1-12.	0.6	12
24	Efficacy and Safety of Mulberry Twig Alkaloids Tablet for the Treatment of Type 2 Diabetes: A Multicenter, Randomized, Double-Blind, Double-Dummy, and Parallel Controlled Clinical Trial. <i>Diabetes Care</i> , 2021, 44, 1324-1333.	4.3	24
25	Incidence of Venous Thromboembolism in Patients With Dermatologist-Diagnosed Chronic Inflammatory Skin Diseases. <i>JAMA Dermatology</i> , 2021, 157, 805.	2.0	21
27	Calibrating Real-World Evidence Studies Against Randomized Trials: Treatment Effectiveness of Infliximab in Crohn's Disease. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 111, 179-186.	2.3	5
28	Glucose-lowering treatments and COVID-19 mortality in T2DM. <i>Nature Reviews Endocrinology</i> , 2021, 17, 387-388.	4.3	7
29	Sulfonylureas Use Is Not Associated With Increased Infarct Size in Patients With Type 2 Diabetes and ST-Segment Elevation Myocardial Infarction. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 658059.	1.1	0
30	Trends in First-Line Glucose-Lowering Drug Use in Adults With Type 2 Diabetes in Light of Emerging Evidence for SGLT-2i and GLP-1RA. <i>Diabetes Care</i> , 2021, 44, 1774-1782.	4.3	24
31	Reply to the Letter by Arterburn D. et al. ("Bias in EHR-based studies: Seeing the Forest for the Trees"). <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1694-1695.	2.2	0
32	Comparative effectiveness and safety of sodium-glucose cotransporter-2 inhibitors versus metformin in patients with type 2 diabetes: An observational study using data from routine care. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 2320-2328.	2.2	12
33	Prevalence of Avoidable and Bias-Inflicting Methodological Pitfalls in Real-World Studies of Medication Safety and Effectiveness. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 111, 209-217.	2.3	12
34	Emulation of a randomized controlled trial in ulcerative colitis with <scp>US</scp> and French claims data: Infliximab with thiopurines compared to infliximab monotherapy. <i>Pharmacoepidemiology and Drug Safety</i> , 2022, 31, 167-175.	0.9	5
35	Role of Gliclazide in safely navigating type 2 diabetes mellitus patients towards euglycemia: Expert opinion from India. <i>Endocrine and Metabolic Science</i> , 2021, 4, 100102.	0.7	0
37	Assessing and Interpreting Real-World Evidence Studies: Introductory Points for New Reviewers. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 111, 145-149.	2.3	9
38	Role of Gliclazide MR in the Management of Type 2 Diabetes: Report of a Symposium on Real-World Evidence and New Perspectives. <i>Diabetes Therapy</i> , 2020, 11, 33-48.	1.2	17
40	Pharmacoepidemiology for nephrologists (part 2): potential biases and how to overcome them. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 1317-1326.	1.4	31
43	Zulassungsverfahren für neue Arzneimittel in Europa. , 2019, , 31-60.		6

#	ARTICLE	IF	CITATIONS
44	Risk of amputation with canagliflozin across categories of age and cardiovascular risk in three US nationwide databases: cohort study. <i>BMJ, The</i> , 2020, 370, m2812.	3.0	7
45	Unicompartmental compared with total knee replacement for patients with multimorbidities: a cohort study using propensity score stratification and inverse probability weighting. <i>Health Technology Assessment</i> , 2021, 25, 1-126.	1.3	6
46	The role of sulfonylureas in the treatment of type 2 diabetes. <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 387-403.	0.9	14
47	Effectiveness of denosumab for fracture prevention in real-world postmenopausal women with osteoporosis: a retrospective cohort study. <i>Osteoporosis International</i> , 2022, 33, 1155-1164.	1.3	11
48	Evolving channeling in prescribing <sc>SGLT</sc> inhibitors as first-line treatment for type 2 diabetes. <i>Pharmacoepidemiology and Drug Safety</i> , 2022, 31, 566-576.	0.9	2
49	A Comparison of Individuals with Diabetes and EMPA-REG Trial Participants: Exploring Aspects of External Validity. <i>Journal of General Internal Medicine</i> , 2022, , 1.	1.3	0
50	Application of Real-World Data to External Control Groups in Oncology Clinical Trial Drug Development. <i>Frontiers in Oncology</i> , 2021, 11, 695936.	1.3	17
51	Cardiovascular Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Older Patients in Routine Clinical Care With or Without History of Atherosclerotic Cardiovascular Diseases or Heart Failure. <i>Journal of the American Heart Association</i> , 2022, 11, e022376.	1.6	14
52	Risk of amputation with canagliflozin across categories of age and cardiovascular risk in three US nationwide databases: cohort study. <i>BMJ, The</i> , 2020, 370, m2812.	3.0	38
53	Incidence of Bacterial and Nonbacterial Conjunctivitis in Patients With Atopic Dermatitis Treated With Dupilumab: A US Multidatabase Cohort Study. <i>Dermatitis</i> , 2022, 33, S73-S82.	0.8	3
54	Durability of the Single-Dose Ad26.COVID.S Vaccine in the Prevention of COVID-19 Infections and Hospitalizations in the US Before and During the Delta Variant Surge. <i>JAMA Network Open</i> , 2022, 5, e222959.	2.8	42
55	Comparative Risk of Alzheimer Disease and Related Dementia Among Medicare Beneficiaries With Rheumatoid Arthritis Treated With Targeted Disease-Modifying Antirheumatic Agents. <i>JAMA Network Open</i> , 2022, 5, e226567.	2.8	16
56	Decreased risk of treatment failure with vedolizumab and thiopurines combined compared with vedolizumab monotherapy in Crohn's disease. <i>Gut</i> , 2022, 71, 1781-1789.	6.1	11
57	Cardiovascular Outcomes in Patients Initiating First-Line Treatment of Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors Versus Metformin. <i>Annals of Internal Medicine</i> , 2022, 175, 927-937.	2.0	20
58	Occurrence of inflammatory bowel disease in patients with chronic inflammatory skin diseases: a cohort study. <i>British Journal of Dermatology</i> , 2022, 187, 692-703.	1.4	19
60	Therapy of Type 2 Diabetes. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2022, 130, S80-S112.	0.6	5
61	Can Observational Analyses of Routinely Collected Data Emulate Randomized Trials? Design and Feasibility of the Observational Patient Evidence for Regulatory Approval Science and Understanding Disease Project. <i>Value in Health</i> , 2023, 26, 176-184.	0.1	8
62	Reproducibility of real-world evidence studies using clinical practice data to inform regulatory and coverage decisions. <i>Nature Communications</i> , 2022, 13, .	5.8	29

#	ARTICLE	IF	CITATIONS
63	Risk of major adverse limb events in patients with type 2 diabetes mellitus receiving sodium glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists: A population-based retrospective cohort study. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	2
64	No association between initiation of phosphodiesterase-5 inhibitors and risk of incident Alzheimer's disease and related dementia: results from the Drug Repurposing for Effective Alzheimer's Medicines study. <i>Brain Communications</i> , 2022, 4, .	1.5	10
65	Comparative Effectiveness of Empagliflozin vs Liraglutide or Sitagliptin in Older Adults With Diverse Patient Characteristics. <i>JAMA Network Open</i> , 2022, 5, e2237606.	2.8	10
66	HARmonized Protocol Template to Enhance Reproducibility of Hypothesis Evaluating Real-World Evidence Studies on Treatment Effects: A Good Practices Report of a Joint ISPE/ISPOR Task Force. <i>Value in Health</i> , 2022, 25, 1663-1672.	0.1	16
67	HARmonized Protocol Template to Enhance Reproducibility of hypothesis evaluating real-world evidence studies on treatment effects: A good practices report of a joint ISPE/ISPOR task force. <i>Pharmacoepidemiology and Drug Safety</i> , 2023, 32, 44-55.	0.9	21
68	Hydroxychloroquine lowers Alzheimer's disease and related dementias risk and rescues molecular phenotypes related to Alzheimer's disease. <i>Molecular Psychiatry</i> , 2023, 28, 1312-1326.	4.1	7
69	An Attempt to Replicate Randomized Trials of Diabetes Treatments Using a Japanese Administrative Claims and Health Checkup Database: A Feasibility Study. <i>Drugs - Real World Outcomes</i> , 0, , .	0.7	0
70	Risk of Infection in Children With Psoriasis Receiving Treatment With Ustekinumab, Etanercept, or Methotrexate Before and After Labeling Expansion. <i>JAMA Dermatology</i> , 2023, 159, 289.	2.0	4
74	Assessment of Fit-for-Use Real-World Data Sources and Applications. , 2023, , 45-61.		0